Yuval Cohen, Ph.D., has been the CEO of Corbus Pharmaceuticals since July 2013. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus successfully developed five novel anti-inflammatory drug programs - including two in Phase II - focusing on allergies and autoimmune diseases of the skin, airways, digestive tract, and eye. He participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fund raising. In March 2013, Dr. Cohen successfully completed a public listing of Celsus in the U.S. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. He attained a Bachelor of Science (Honors) from the University of Cape Town (South Africa) before being awarded the prestigious BGF Scholarship from the French foreign ministry to carry out his doctoral studies in Paris.
The pharmaceutical industry is constantly evolving. There always seem to be new, innovative therapeutic approaches emerging that capture our imagination and advance our ability to make a difference in the lives... Read more »
June 12, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.